SCHEMBL29378366

SCHEMBL29378366

COc1cccc2c1C(=O)NC2=O

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TOP1 P11387 1/20 0.55
CA1 P00915 1/20 0.54
CA2 P00918 1/20 0.54
CA7 P43166 1/20 0.54
CA9 Q16790 1/20 0.54
CASP3 P42574 1/20 0.52
KCNA5 P22460 1/20 0.51
STK10 O94804 6/20 0.50
SLK Q9H2G2 6/20 0.50
GSK3B P49841 5/20 0.50
ALDH1A1 P00352 3/20 0.50
MEN1 O00255 2/20 0.50
KMT2A Q03164 2/20 0.50
MAPT P10636 2/20 0.50
KDM4E B2RXH2 2/20 0.50
CLK2 P49760 1/20 0.50
GSK3A P49840 1/20 0.50
STK33 Q9BYT3 1/20 0.50
CLK4 Q9HAZ1 1/20 0.50
TLK1 Q9UKI8 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL384815 1.00 TOP1 (0.55) TOP1CA1CA2CA7CA9
SCHEMBL9768590 0.85 KDM4E (0.51) TOP1CA1CA2CA7CA9
SCHEMBL262473 0.84 GSK3B (0.50) CASP3KCNA5STK10SLKGSK3B
SCHEMBL28099802 0.84 GSK3B (0.50) CASP3KCNA5STK10SLKGSK3B
SCHEMBL1477960 0.84 CA1 (0.50) TOP1CA1CA2CA7CA9
SCHEMBL27447700 0.81 STK10 (0.64) CASP3STK10SLKGSK3BALDH1A1
SCHEMBL7399139 0.80 DDB1 (0.46) CASP3GSK3BALDH1A1MEN1KMT2A
SCHEMBL4869329 0.80 CA1 (0.58) CA1CA2CA7CA9CASP3
SCHEMBL28678417 0.80 PARP1 (0.58) TOP1CA1CA2CA7CA9
SCHEMBL7964993 0.79 CA1 (0.56) CA1CA2CA7CA9STK10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4206205-B1 PREPARATION METHOD FOR PYRROLOPYRIMIDINE COMPOUND PRIMEGENE BEIJING CO LTD (CN) 2026-03-04 EP claimed
EP-4232445-A1 COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR PROTEIN Arvinas Operations, Inc. (US) 2023-08-30 EP disclosed
WO-2022087125-A1 COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR PROTEIN ARVINAS OPERATIONS, INC. (US) 2022-04-28 WO disclosed
US-20220041578-A1 ISOINDOLINE COMPOUND, AND PREPARATION METHOD, PHARMACEUTICAL COMPOSITION, AND APPLICATION OF ISOINDOLINE COMPOUND SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) 2022-02-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220041578-A1 ISOINDOLINE COMPOUND, AND PREPARATION METHOD, PHARMACEUTICAL COMPOSITION, AND APPLICATION OF ISOINDOLINE COMPOUND CRBN, CUL4B, UBQLN1 TOP1 1685/4885CA1 4258/4885CA2 4479/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.